AAAAAA

   
Results: 1-16 |
Results: 16
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer
Authors: Tartour, E Mosseri, V Jouffroy, T Deneux, L Jaulerry, C Brunin, F Fridman, WH Rodriguez, J
Citation: E. Tartour et al., Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer, LANCET, 357(9264), 2001, pp. 1263-1264
Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy inpatients with breast cancer
Authors: Scholl, SM Balloul, JM Le Goc, G Bizouarne, N Schatz, C Kieny, MP von Mensdorff-Pouilly, S Vincent-Salomon, A Deneux, L Tartour, E Fridman, W Pouillart, P Acres, B
Citation: Sm. Scholl et al., Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy inpatients with breast cancer, J IMMUNOTH, 23(5), 2000, pp. 570-580
In situ PCR: an overview
Authors: Tartour, E Gey, A Hamdi, S Vielh, P Nagarajan, B Fridman, WH
Citation: E. Tartour et al., In situ PCR: an overview, ANN PATHOL, 20(3), 2000, pp. 213-220
Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line
Authors: Cassard, L Dragon-Durey, MA Ralli, A Tartour, E Salamero, J Fridman, WH Sautes-Fridman, C
Citation: L. Cassard et al., Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line, IMMUNOL LET, 75(1), 2000, pp. 1-8
Cancer vaccines 2000
Authors: Tartour, E Fridman, WH
Citation: E. Tartour et Wh. Fridman, Cancer vaccines 2000, IMMUNOL LET, 74(1), 2000, pp. 1-3
Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvants...) as tools for cancer vaccines
Authors: Tartour, E Ciree, A Haicheur, N Benchetrit, F Fridman, WH
Citation: E. Tartour et al., Development of non-live vectors and procedures (liposomes, pseudo-viral particles, toxin, beads, adjuvants...) as tools for cancer vaccines, IMMUNOL LET, 74(1), 2000, pp. 45-50
The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
Authors: Haicheur, N Bismuth, E Bosset, S Adotevi, O Warnier, G Lacabanne, V Regnault, A Desaymard, C Amigorena, S Ricciardi-Castagnoli, P Goud, B Fridman, WH Johannes, L Tartour, E
Citation: N. Haicheur et al., The B subunit of shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens, J IMMUNOL, 165(6), 2000, pp. 3301-3308
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
Authors: Haicheur, N Escudier, B Dorval, T Negrier, S De Mulder, PHM Dupuy, JM Novick, D Guillot, T Wolf, S Pouillart, P Fridman, WH Tartour, E
Citation: N. Haicheur et al., Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients, CLIN EXP IM, 119(1), 2000, pp. 28-37
Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings
Authors: Tartour, E Mehtali, M Sastre-Garau, X Joyeux, I Mathiot, C Pleau, J Squiban, P Rochlitz, C Courtney, M Jantscheff, P Herrmann, R Pouillart, P Fridman, WH Dorval, T
Citation: E. Tartour et al., Phase I clinical trial with IL-2-transfected xenogeneic cells administeredin subcutaneous metastatic tumours: clinical and immunological findings, BR J CANC, 83(11), 2000, pp. 1454-1461
Soluble CD16 in plasma cell dyscrasias
Authors: Mathiot, C Galon, J Tartour, E Teillaud, JL Facon, T Bataille, R Fridman, WH Sautes, C
Citation: C. Mathiot et al., Soluble CD16 in plasma cell dyscrasias, LEUK LYMPH, 32(5-6), 1999, pp. 467-474
Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
Authors: Rochlitz, C Jantscheff, P Bongartz, G Dietrich, PY Quiquerez, AL Schatz, C Mehtali, M Courtney, M Tartour, E Dorval, T Fridman, WH Herrmann, R
Citation: C. Rochlitz et al., Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors, CANC GENE T, 6(3), 1999, pp. 271-281
Control of tumor development by intratumoral cytokines
Authors: Pages, F Vives, V Sautes-Fridman, C Fossiez, F Berger, A Cugnenc, PH Tartour, E Fridman, WH
Citation: F. Pages et al., Control of tumor development by intratumoral cytokines, IMMUNOL LET, 68(1), 1999, pp. 135-139
Defective IL2 gene expression in newborn is accompanied with impaired tyrosine-phosphorylation in T cells
Authors: Ansart-Pirenne, H Soulimani, N Tartour, E Blot, P Sterkers, G
Citation: H. Ansart-pirenne et al., Defective IL2 gene expression in newborn is accompanied with impaired tyrosine-phosphorylation in T cells, PEDIAT RES, 45(3), 1999, pp. 409-413
Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells
Authors: Gey, A Hamdi, S Vielh, P Mehtali, M Fridman, WH Tartour, E
Citation: A. Gey et al., Development of a direct in situ RT-PCR method using labeled primers to detect cytokine mRNA inside cells, J IMMUNOL M, 227(1-2), 1999, pp. 149-160
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice
Authors: Tartour, E Fossiez, F Joyeux, I Galinha, A Gey, A Claret, E Sastre-Garau, X Couturier, J Mosseri, V Vives, V Banchereau, J Fridman, WH Wijdenes, J Lebecque, S Sautes-Fridman, C
Citation: E. Tartour et al., Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice, CANCER RES, 59(15), 1999, pp. 3698-3704
Tumor immunology: a new look
Authors: Fridman, WH Pages, F Michon, J Teillaud, JL Tartour, E
Citation: Wh. Fridman et al., Tumor immunology: a new look, RESEARCH IN, 1998, pp. 3-22
Risultati: 1-16 |